Second FDA-Approved OTC Opioid Overdose Reversal Medication – Shiv Telegram Media
2 min read
FDA Approves New Over-The-Counter Medication RiVive to Combat Opioid Overdose
In a significant move towards addressing the opioid crisis, the Food and Drug Administration (FDA) has recently approved RiVive, an over-the-counter opioid overdose reversal medication. Developed as a nasal spray, RiVive contains 3 mg of naloxone hydrochloride and is now the second nonprescription emergency treatment for known or suspected opioid overdose on the market.
The approval of RiVive follows the successful nonprescription use approval of Narcan in March 2023. The decision was supported by a study demonstrating the effectiveness of RiVive in reaching the bloodstream, which was found to be comparable to prescription naloxone products.
One of the most significant advantages of RiVive is that it can be used safely and effectively without the need for medical supervision. Consumers can easily understand how to administer the nasal spray, making it a crucial tool in addressing opioid overdoses. However, it is important to note that the use of RiVive in individuals dependent on opioids may result in severe withdrawal symptoms.
The opioid crisis has plagued the United States, causing a staggering number of deaths. In 2021 alone, over 107,000 Americans lost their lives to drug overdoses. Alarmingly, synthetic opioids containing fentanyl were responsible for more than 70,000 of these deaths. The availability of RiVive as an over-the-counter medication brings hope for saving lives and reducing these alarming statistics.
Recent research has also shed light on the devastating impact of opioids on younger generations. Unintentional drug overdoses have led to a significant increase in “Years of Life Lost” (YLL) among adolescents and youth. It is crucial to prioritize preventive measures and ensure access to life-saving medications like RiVive to protect these vulnerable populations.
While discussing medications for opioid overdose, it is essential to address the issue of affordability. The cost of naloxone, even before the introduction of RiVive, has been a point of concern. Without insurance coverage, a single dose of naloxone can range from approximately $120 to $150 or more. Raising awareness about available discounts and financial assistance options for those who cannot afford naloxone is of utmost importance.
The availability and pricing of RiVive will be determined by the manufacturer. However, the FDA has emphasized the significance of ensuring widespread access to naloxone products in order to protect public health. With the approval of RiVive, individuals and communities will have another critical tool in their hands to combat the opioid crisis and save lives.
For more information about the FDA’s approval of RiVive, please visit [website]
“Communicator. Award-winning creator. Certified twitter geek. Music ninja. General web evangelist.”
